Peptide Complex for Anti-Obesity and Diabetes via Lipid Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity and anti-diabetes drugs face challenges such as side effects, limited applicability to patients with heart or kidney issues, high treatment costs, and difficulties in managing blood sugar levels effectively, particularly for obesity-induced diabetes.
Innovation Solution
Development of peptides with specific amino acid sequences (SEQ ID NOS: 1 to 7) that suppress fat accumulation, degrade accumulated fat, and regulate insulin signaling, which are used alone or in combination to form a peptide complex for therapeutic application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-obesity drugs act on the central nervous system or gastrointestinal tract, then appetite control or fat uptake inhibition is achieved, but serious side effects occur such as pulmonary hypertension, valvular heart disease, blood pressure reduction, or lactic acidosis
Solution Approach 1:
The patent introduces a novel peptide structure as an intermediary substance that mediates between the therapeutic goal (fat metabolism regulation) and safety requirements. The peptide acts through a unique mechanism involving specific amino acid sequences that regulate lipid metabolism without the harmful side effects of CNS or gastrointestinal tract acting drugs, thereby resolving the contradiction between effectiveness and safety
Solution Approach 2:
The patent changes the fundamental parameter of drug action mechanism by developing a peptide that acts through lipid metabolism regulation rather than through CNS or gastrointestinal pathways. This parameter change allows achieving therapeutic effects while avoiding the side effects associated with traditional action mechanisms
2Adaptability or versatility
If existing anti-obesity drugs are used for obesity treatment, then weight management is achieved, but applicability is limited for patients with heart failure or kidney failure
Solution Approach 1:
The patent creates a peptide with universal applicability across different patient populations including those with heart failure or kidney failure. The peptide's mechanism of action through lipid metabolism regulation does not contraindicate with these conditions, making it universally applicable while maintaining safety, thus resolving the contradiction between adaptability and reliability
3Reliability
If insulin is used for blood sugar control in diabetes patients, then blood sugar management is improved, but weight gain and hypoglycemic risk occur
Solution Approach 1:
The patent converts the harmful effect of lipid accumulation into a beneficial therapeutic target. By developing a peptide that specifically regulates lipid metabolism, the invention addresses the root cause of insulin resistance and diabetes complications without producing the harmful effects of insulin therapy, thereby resolving the contradiction between blood sugar control and weight gain/hypoglycemia risks
Data Source
AI summary
A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.